Ostarine, also known as MK-2866 or enobosarm, is a selective androgen receptor modulator.
We also have Ostarine capsules if you’re interested.
A phase 2a study has shown that Ostarine treatment may have potentially improved lean body mass, decreased fat mass, and enhanced stair climbing ability in healthy older men and women.
In a clinical study, Ostarine exhibited the potential ability to decrease fasting blood glucose, low-density lipoprotein (LDL) cholesterol, and insulin resistance.
Various animal studies have shown that Ostarine could potentially improve bone healing, bone mineral density, and bone volume density.
Behemoth Labz sells Ostarine for laboratory research use only.
Keep contents sealed and stored in a cool dry place. Items are shipped in a plain envelope or bubble mailer within 24-48 hours (or next business day)
Ostarine is an orally bioavailable, non-steroidal SARM. It was initially developed as a potential treatment for muscle wasting and osteoporosis. In clinical trials, Ostarine has shown the potential ability to increase total lean body mass in healthy subjects as well as cancer patients. [R][R]
Ostarine might also potentially prove to be beneficial for people with heart disease. In a clinical trial of 120 healthy older adults, MK-2866 was found to potentially lower glycerides, total cholesterol, and LDL cholesterol. Low triglyceride levels are considered vital to prevent heart disease. [R]
In the above study, Ostarine may have lowered blood glucose and improved insulin resistance. This SARM was also found to potentially lower insulin levels in the bloodstream. Ostarine’s potential effects on these markers were found to be similar to those of standard anti-diabetic compounds such as metformin.
Animal studies have highlighted this research chemical’s potential positive effects on bone health. At least two pre-clinical studies have shown that Ostarine has the potential to increase bone strength. This SARM also may have potentially increased bone mineral and volume density, and was found to expedite bone healing. [R]
Ostarine, like other SARMs, selectively binds to androgen receptors (ARs). MK-2866 has demonstrated potential tissue-selective anabolic effects in muscle and bone, while it may be sparing other androgenic tissues related to hair growth in women and prostate effects in men. [R]
In animal studies, Ostarine had the potential for increased muscle mass and bone density while having limited effects on other AR-responsive tissues, including the prostate and seminal vesicles. In fact, prostate size was potentially reduced at doses that increased muscle mass in intact, male rats.
Behemoth Labz doesn’t sell Ostarine for human consumption.
Similar to RAD 140, multiple clinical and pre-clinical studies have shown that Ostarine has the potential to increase lean muscle mass, reduces fat mass, and improves physical function in adults.
MK-2866 might also offer a promising option for the prevention and treatment of muscle wasting caused by cancer.
However, while it’s still being medically researched, Ostarine is banned by the World Anti-Doping Agency. It is currently listed under the S1 Anabolic Agent category of WADA’s Prohibited List. The FDA is also yet to approve this research chemical for human consumption.
In a phase 1 study involving 48 healthy men and 28 elderly males with truncal obesity, Ostarine treatment for 14 days had the potential for increased lean body mass. Ostarine also demonstrated a potential favorable safety profile without adverse effects involving the skin or prostate. [R]
In a double-blind, placebo-controlled phase II trial, Ostarine may have improved lean body mass and physical function in healthy elderly men and postmenopausal women. That, too, without the adverse consequences often seen with testosterone and other anabolic compounds. [R]
In a phase 2 trial, Ostarine treatment caused potentially significant increases in total lean body mass in cancer cachexia patients. Cancer cachexia is a syndrome characterized by the continuous loss of skeletal muscle mass (muscle wasting). Around 15%-20% of cancer patients are affected by cachexia. [R]
In addition to potentially increasing lean body mass, Ostarine treatment may have significantly decreased the median time cancer cachexia patients required to climb 12 stairs. Ostarine could thus offer a promising option for the prevention and treatment of muscle wasting due to cancer.
MK-2866 is currently undergoing phase 3 trials for the treatment of cancer cachexia. [R]
In the above phase 2 trial, a 3-mg Ostarine dose caused a potentially significant decrease in total fat mass among healthy elderly men and postmenopausal women. The differences in changes in fat mass in the 3-mg group were 0.6 kg higher than members of the placebo group.
Notably, despite the reduction in body fat, no differences in total body weight were observed in the 3-mg group. This indicates that a shift to leaner body composition was achieved, at least partially, at the expense of body fat.
An animal study has found that Ostarine treatment may prevent bone loss in ovariectomized rats. Results from the study show that Ostarine treatment prevented bone loss and improved bone strength, suggesting a possible role for this SARM in osteoporosis treatment. [R]
Another pre-clinical study explored the effects of Ostarine on osteoporotic bone. This study observed significant potential improvements in structural properties of bone, such as bone volume density and bone volume density. Further studies are needed to investigate the effects of MK-2866 on osteoporosis. [R]
In a pre-clinical study, Ostarine showed potential to inhibit proliferation and tumor growth of AR+ triple-negative breast cancer (TNBC). Compared to vehicle-treated tumors, MK-2866 treatment may have inhibited tumor growth and tumor weight by greater than 90%. [R]
An open-label phase 2 study explored the safety and efficacy of the combination of MK-2866 and Pembrolizumab for AR+ TNBC. Pembrolizumab is a compound already used in cancer immunotherapy to treat multiple types of cancers, including breast cancer. [R][R]
Results from the study indicate that the combination of the two compounds was well-tolerated. It also showed a modest clinical benefit rate of 25% at 16 weeks.
A 12-week trial was conducted to investigate the potential effects of Ostarine treatment in healthy elderly men and postmenopausal women. Researchers divided the trial’s subjects into three different groups: 0.3-mg, 1-mg, and 3-mg. [R]
Results from the study show that Ostarine administration may have decreased serum triglycerides in the last two groups compared to placebo. All three groups also experienced a potential statistically significant reduction in total cholesterol and HDL cholesterol.
In the above phase 2 trial, Ostarine 3 mg administration potentially significantly reduced fasting glucose levels in healthy men and women. These effects may have caused a decrease in insulin resistance similar to that observed with standard compounds used in the treatment of diabetes. [R]
This may mean that researching a compound like MK 677 that has the potential ability to decrease insulin sensitivity, with a compound like Ostarine, may undo this unwanted effect.
Selective androgen receptor modulators are small molecule compounds that selectively bind to androgen receptors in the body.
Their tissue-specific action may enable SARMs to target ARs in the muscle and bone tissue, mainly sparing reproductive organs.
According to multiple clinical studies, Ostarine MK-2866 has a half-life of 24 hours.
In a clinical trial, 3-mg Ostarine administration didn’t cause testosterone suppression. So, a potential post cycle therapy may not be needed.
Behemoth Labz is the best place to buy MK 2866 Ostarine online.
We have been around since 2014, supplying the highest-quality research compounds money can buy. All of our products come with a 100% satisfaction guarantee, free and fast shipping, and a money-back guarantee. We carry liquid Ostarine and Ostarine capsules.
In multiple clinical studies, Ostarine has demonstrated the potential ability to increase muscle gain, decrease fat mass and improve blood glucose levels. In addition, MK-2866 may have potentially reduced bone strength, bone volume, and mineral densities in pre-clinical studies.
Please make sure you go through the Terms and Conditions, and please familiarize yourself with it as it is important. Please research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.
Buying the product means you agree with our Terms and Conditions. You can contact our awesome customer service team at email@example.com if you are not fully satisfied with the product. Customer satisfaction is our number one priority!
ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human and veterinary purposes.